论文信息 - LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders - 字舞流文

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

D. McKinzie | Xia Li | J. Witkin | J. McKinzie | M. Statnick | C. Mitch | S. Quimby | Nuria Díaz | C. Pedregal | Alma Jiménez | L. Rorick-Kehn | W. H. Anderson | J. Cramer | Conrad J. Wong | Beth M. Forster | K. Knopp | A. E. Sahr | David B. Shaw | E. L. Eberle | B. Adams | S. Kahl | Robert S. Crile | L. Rorick‐Kehn | W. Anderson